[Allergic disease treatments: classic and innovative therapeutics].
The purpose of this article is to focus on anti-allergic therapies that directly target cellular or humoral actors of the allergic reaction and which are quasi-exclusively dedicated to the treatment of allergic diseases. This leads to successively look at: anti-histamines, classic treatments but in constant improvement, allergen immunotherapy which is experiencing a second life with the validation of the sublingual route and monoclonal anti-IgE antibody, a real new therapeutic class which has demonstrated his efficacy in patients with severe non-controlled allergic asthma.
Têtu
Laurent
L
Clinique des voies respiratoires, CHU de Toulouse, hôpital Larrey, TSA 30030, 31059 Toulouse.
Didier
Alain
A
D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003888:Desensitization, Immunologic; D006634:Histamine H1 Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D007073:Immunoglobulin E / Q000276:immunology; D000069444:Omalizumab
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006634:Histamine H1 Antagonists; D000069444:Omalizumab; D007073:Immunoglobulin E